iRhythm Technologies, Inc.

IRTC

US4500561067

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 21:00:00 11/12/2024 GMT			5-day change	1st Jan Change
89.93 ^USD	+3.49%		+3.61%	-15.98%

12-04	IRhythm Technologies, Inc. Presents at Citi's 2024 Global Healthcare Conference, Dec-04-2024 10:15 AM
12-03	Wells Fargo Downgrades iRhythm Technologies to Equalweight, Price Target is $86	MT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about iRhythm Technologies, Inc.

IRhythm Technologies, Inc. Presents at Citi's 2024 Global Healthcare Conference, Dec-04-2024 10:15 AM	12-04
Wells Fargo Downgrades iRhythm Technologies to Equalweight, Price Target is $86	12-03	MT
Integra LifeSciences Holdings Corporation Announces Chief Executive Officer Changes	11-04	CI
Integra LifeSciences Holdings Corporation Announces Executive Changes	11-04	CI
Earnings Flash (IRTC) IRHYTHM Reports Q3 Loss $-1.26	10-30	MT
Earnings Flash (IRTC) IRHYTHM Posts Q3 Revenue $147.5M	10-30	MT
IRhythm Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	10-30	CI
IRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device	10-30	CI
IRhythm Technologies, Inc., Q3 2024 Earnings Call, Oct 30, 2024	10-30
IRhythm Technologies, Inc. Provides Earnings Guidance for the Year 2024	10-30	CI
Truist Raises Price Target on iRhythm Technologies to $95 From $80, Keeps Buy Rating	10-22	MT
IRhythm Gets FDA Clearance for Design Updates Made to Zio AT Device; Shares Rise After-Hours	10-21	MT
IRhythm Technologies, Inc. Receives FDA 510(k) Clearance for Design Updates Previously Made to Its Zio AT Device	10-21	CI
Truist Cuts Price Target on iRhythm Technologies to $80 From $117, Keeps Buy Rating	10-14	MT
Goldman Sachs Initiates iRhythm Technologies at Neutral With $78 Price Target	10-04	MT
IRhythm Technologies Secures Japanese Approval for EGC Monitoring Device	09-11	MT
IRhythm Technologies, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 03:20 PM	09-04
IRhythm Technologies Signs License Agreement With BioIntelliSense for Multiparameter Sensor Technology	09-04	MT
IRhythm Technologies, Inc. Reaffirms Earnings Guidance for the Year 2024	09-04	CI
IRhythm Technologies, Inc. Announces Results of GUARD-AF Trial	09-01	CI
IRhythm Technologies Commercially Rolls out Zio Monitor, Zio LTCM ECG Service in Four European Countries	08-29	MT
Needham Adjusts iRhythm Technologies' PT to $119 From $138, Keeps Buy Rating	08-02	MT
Truist Adjusts iRhythm Technologies' PT to $117 From $134, Keeps Buy Rating	08-02	MT
Oppenheimer Adjusts iRhythm Technologies Price Target to $145 From $165, Maintains Outperform Rating	08-02	MT
IRhythm Technologies Appoints Daniel Wilson as Finance Chief	08-02	MT

Chart iRhythm Technologies, Inc.

Duration

Period

IRTC: Dynamic Chart

iRhythm Technologies, Inc. is a digital health care company, which creates solutions that detect, predict, and prevent disease. The Company designs, develops, and commercializes device-based technology to provide ambulatory cardiac monitoring services. It offers three Zio System options: the Zio Monitor System, the Zio XT System, and the Zio AT System. It offers its Zio ambulatory cardiac monitoring services, including long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry monitoring services (Zio Services), using its Zio Systems. The Zio Monitor System is a prescription-only, remote ECG monitoring system that consists of a patch ECG monitor (the Zio Monitor patch) that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software (ZEUS) System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period.

Employees

2,000

Sector

Advanced Medical Equipment & Technology

Calendar

19/02/2025 - Q4 2024 Earnings Release (Projected)

More about the company